Reports say Moderna has begun early-stage research into a hantavirus vaccine, a development that immediately moved investor expectations and reignited interest in unmet infectious-disease prevention needs. The work is described as in the earliest phases, a point that typically precedes years of clinical development. The reports link Moderna’s activity to collaborations with the US Army Medical Research Institute of Infectious Diseases and Korea University’s Vaccine Innovation Center, according to coverage cited by investors. Notably, there is currently no approved vaccine for hantavirus disease, and the virus is carried by rodents. The news arrives as global attention increased after a hantavirus cluster tied to cruise travel was reported by the World Health Organization, with confirmed cases and deaths. While Moderna has not provided clinical timelines, the company’s history of rapid platform mobilization keeps the market focused on next infectious-disease targets.